研究领域标准
病理学
重性抑郁障碍
抗抑郁药
精神科
心理学
透视图(图形)
医学
临床心理学
心理健康
心理治疗师
计算机科学
人工智能
焦虑
心情
作者
Marco Calabró,Chiara Fabbri,Siegfried Kasper,Joseph Zohar,Daniel Souery,Stuart Montgomery,Diego Albani,Gianluigi Forloni,Panagiotis Ferentinos,Dan Rujescu,Julien Mendlewicz,Roberto Colombo,Diana De Ronchi,Alessandro Serretti,Concetta Crisafulli
标识
DOI:10.2174/0929867328666210104104938
摘要
Background: Major Depressive Disorder(MDD) and its frequent partial response to antidepressants are a major health concern and therefore an important focus of research. Despite the efforts, MDD pathogenesis and the mechanisms of antidepressant action are only partially understood. In the last few years, the need of rethinking the classification of depressive disorders and psychiatric disorders, in general, has been suggested, in order to provide a nosology that reflects more closely the biological background associated with disease pathogenesis and its role/significance in treatment. The classification proposed by the National Institute of Mental Health (NIMH), namely the research domain criteria (RDoC), may represent a key framework to guide research in this direction. Methods: A literature search was performed on PubMed and Google Scholar databases in order to retrieve data regarding Antidepressants effects on specific RDoC constructs. Further, the targets of drugs of interest were identified through the Drug bank database, and their possible function within RDoC constructs was discussed. Discussion: In this review, we summarize and discuss the significance of the results of pre-clinical and clinical studies investigating specific RDoC paradigms relevant to depressive phenotypes and antidepressant effects. Conclusion: The RDoC framework may facilitate a more specific use of antidepressants based on the individual’s spectrum of symptoms and the development of new compounds that target specific depressive symptoms.
科研通智能强力驱动
Strongly Powered by AbleSci AI